Monday, April 7, 2014

Coming Soon: PeriRx LLC’s Breakthrough Salivary Test to Aid in the Fight Against Oral Cancer

As most of you regular readers know, I'm very passionate about oral cancer detection.  Oral cancer is a terribly debilitating and potentially disfiguring disease that my profession is constantly on the lookout for.  One person every hour dies of this horrible disease and those that survive can suffer terrible loss of quality of life.

We all need to be doing everything within our power to find and irradiate this disease.  If caught early, it can be treated conservatively.  However, if it is caught late, aggressive treatment is frequently needed.  If caught in stage 3 or 4, the five year survival rate is low.

So the point is, we all need to be doing as much as possible to find this disease in its earliest and smallest stages.  That is why I frequently post here about screening for oral cancer as well as products that can help practitioners detect it early.

That's why I was excited to get the following press release.  Anything that holds the promise of helping to detecting oral cancer as soon as possible, bears mentioning here.

 

The World’s Most Clinically Advanced and Scientifically Validated Molecular DNA Biomarker Test for Oral Squamous Cell Carcinoma is Launching in Late Spring

 

 

Havertown, PA – April 3, 2014 – PeriRx LLC, a premier developer of breakthrough, non-invasive, oral diagnostic technology recently announced that it will be introducing the world’s most clinically advanced and scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma detection in the late spring.

 

According to PeriRx LLC’s CEO Stephen M. Swanick, “This is a simple-to-use, painless and noninvasive test designed for front line healthcare practitioners that enables them to detect disease earlier, enhance patient wellness and reduce the overall cost of healthcare.”  

.

The salivary test is based on a strong scientific foundation of NIH-funded research with initial discovery and pre-validation work by Dr. David Wong of the University of California at Los Angeles. The test also has the distinction of being the first of its kind assay in the world to aid in the identification and early detection of oral lesions at the highest risk for cancer.

 

These discriminatory salivary biomarkers have been clinically validated in multiple large trials including studies in collaboration with the National Cancer Institute and with premiere US academic medical centers such as the University of Michigan, Michigan State University and the Providence Health System in Detroit.

For more information, visit www.PeriRx.com. To become an early adopter of the salivary test, or to become an investor in PeriRx LLC, contact Stephen M. Swanick at 610-449-9625 or perirx@rcn.com. 

 

About PeriRx LLC:

 

Based in Havertown, Pennsylvania, PeriRx LLC is a premier developer of breakthrough, non-invasive, oral diagnostic technology that will help clinical professionals detect and treat diseases sooner and enhance the practice of wellness management.  

The company was founded in 2008 to explore, innovate, and develop novel therapeutics or devices focused on the oral inflammatory/systemic connection. The PeriRx executive team consists of CEO Stephen M. Swanick, an entrepreneur and experienced drug and device development professional; Dr. Neil Gottehrer, a practicing dentist; and Dr. Jack Martin, a cardiologist. 

 

PeriRx obtained its patented and patent-pending technologies from inventor Dr. David Wong’s firm RNAmeTRIX and the Regents of the University of California at Los Angeles. PeriRx and RNAmeTrix have ongoing agreements which ensure the continuing research and development necessary to advance product development from clinical trial, through FDA approval, and into commercialization.


Post a Comment